B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2014-08-01
  Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. [Phase 1]

  Phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of a recombinant chimeric anti-CD20 monoclonal antibody in patients …

• CLINICAL_TRIALS trial_result · 2013-07-11
  Clinical Trial Update: Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia [Phase 2]

  A Phase 2 trial evaluated the combination of epirubicin and rituximab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma or…

• CLINICAL_TRIALS trial_result · 2013-06-25
  Clinical Trial Update: Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Other B-cell Cancers [Phase 2]

  This Phase 2 trial update reports on the use of pentostatin, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia a…

• CLINICAL_TRIALS trial_result · 2013-05-22
  Clinical Trial Update: Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) [Phase 1]

  This Phase 1 trial of MDX-1203 in patients with clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma has comp…

• CLINICAL_TRIALS trial_result · 2013-04-15
  Clinical Trial Update: Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma [Phase 2]

  Phase 2 trial update reporting completion and posted results for chemotherapy with a monoclonal antibody and radioimmunotherapy in high-risk…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2012-07-09
  Clinical Trial Update: Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) [Phase 1, Phase 2]

  This update summarizes Phase 1/2 trial results for clo farabine in relapsed or refractory T-cell or B-cell non-Hodgkin lymphoma.

• CLINICAL_TRIALS trial_result · 2012-03-14
  Clinical Trial Update: A Study of ONTAK in Patients With Relapsed or Refractory, B-Cell Non Hodgkin's Lymphoma [Phase 2]

  Phase 2 clinical trial update for ONTAK (denileukin diftitox) in relapsed or refractory B-cell non-Hodgkin lymphoma; the study has completed…

• CLINICAL_TRIALS trial_result · 2012-02-14
  Clinical Trial Update: Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma [Phase 1]

  Phase 1 multi-dose escalation trial evaluating the safety and pharmacokinetics of SAR3419 as a single agent in relapsed/refractory B-cell no…

• CLINICAL_TRIALS trial_result · 2011-07-26
  Clinical Trial Update: Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 3]

  A Phase 3 trial evaluating Velcade (bortezomib) in combination with Rituximab for relapsed or refractory B-cell non-Hodgkin lymphoma has bee…

• CLINICAL_TRIALS trial_result · 2010-07-30
  Clinical Trial Update: Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma [Phase 2]

  This update reports a phase 2 salvage therapy trial of idarubicin for relapsing primary central nervous system lymphoma, sponsored by IELSG,…

• CLINICAL_TRIALS trial_result · 2009-06-25
  Clinical Trial Update: Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL) [Phase 2]

  This is an interventional Phase 2 trial evaluating a pentostatin, cyclophosphamide, and rituximab regimen for indolent B-cell non-Hodgkin ly…

• CLINICAL_TRIALS trial_result · 2008-03-04
  Clinical Trial Update: A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell Lymphoma [Phase 1]

  It notes the completion of a Phase I trial evaluating the continuous infusion immunotoxin IgG-RFB4-SMPT-dgA in refractory CD22-positive B-ce…

• CLINICAL_TRIALS trial_result · 2008-01-28
  Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 2]

  A Phase 2 trial of bortezomib combined with rituximab for relapsed or refractory B-cell non-Hodgkin's lymphoma was terminated.